6 unchanged sentences
We have never declared or paid any dividends and do not anticipate paying any dividends on our common stock in the foreseeable future.
−Removed: Comparative Stock Performance Graph
−Removed: The information included under the heading “Comparative Stock Performance Graph” in this Item 5 of Part II of this Form 10-K shall not be deemed to be “soliciting material” or subject to Regulation 14A or 14C, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act.
−Removed: Set forth below is a graph comparing the total cumulative returns of our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index.
−Removed: The graph assumes $100 was invested in our common stock and each of the indices on December 31, 2015 and that all dividends, if any, are reinvested.
−Removed: * $100 invested on December 31, 2015 in stock or index, including reinvestment of dividends.
−Removed: Assembly Biosciences, Inc.
−Removed: Nasdaq Composite
−Removed: Nasdaq Biotechnology
Securities Authorized for Issuance Under Equity Compensation Plans
13 unchanged sentences
This number excludes purchase rights currently accruing under the Assembly Biosciences, Inc.
−Removed: 2018 Employee Stock Purchase Plan (2018 ESPP).
+Added: Amended and Restated 2018 Employee Stock Purchase Plan (2018 ESPP).
This number includes:
1 unchanged sentence
733,295 shares available for issuance under the 2014 Plan;
−Removed: 2,037,029 shares available for issuance under the 2018 Plan and;
−Removed: 232,335 shares reserved for issuance under the 2018 ESPP.
+Added: 3,337,448 shares available for issuance under the 2018 Plan ;
+Added: and 1,043,515 shares reserved for issuance under the 2018 ESPP .
As of February 2 8 , 20 2 2 , assuming each participant purchases the maximum number of shares in the current offering period, no more than 155,000 shares are subject to purchase in the current offering, which ends on May 1 3 , 20 2 2 .
1 unchanged sentence
500,000 shares subject to stock options granted under the 2019 Inducement Award Plan (2019 Inducement Plan);
+Added: and 764,290 shares subject to outstanding awards granted under the 2020 Inducement Award Plan (2020 Inducement Plan), of which 693,040 were subject to outstanding stock options and 71,250 were subject to outstanding RSUs.
This number includes:
−Removed: 700 shares available for issuance under the 2017 Inducement Plan and no shares under the 2019 Inducement Plan.
+Added: 191,288 shares available for issuance under the 2017 Inducement Plan, no shares under the 2019 Inducement Plan and 11,960 shares available for issuance under the 2020 Inducement Plan.
Our stockholder-approved equity compensation plans consist of the 2018 Plan, 2014 Plan, the 2010 Plan, stock options assumed in our merger with Assembly Pharmaceuticals and the 2018 ESPP.
2 unchanged sentences
An “Award” under the 2018 Plan, 2014 Plan or 2010 Plan is any right to receive our common stock consisting of non-statutory stock options, incentive stock options, stock appreciation rights, RSUs, or any other stock award.
−Removed: In May 2018, our stockholders approved the 2018 ESPP.
+Added: In May 2018, our stockholders approved the 2018 ESPP and was amended and restated in May 2021.
The 2018 ESPP provides for the purchase by employees of up to an aggregate of 1,300,000 shares of the Company’s common stock.
Eligible employees can purchase shares of our common stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period.
−Removed: Our outstanding equity compensation arrangements that have not been approved by our stockholders consist of the 2017 Inducement Plan, the 2019 Inducement Plan and warrants to purchase shares of our common stock issued to one consultant.
−Removed: In April 2017, our board of directors adopted the 2017 Inducement Plan and reserved 800,000 shares of our common stock for issuance under the Inducement Plan, and in August 2019, our board of directors adopted the 2019 Inducement Plan and reserved 500,000 shares of our common stock for issuance under the 2019 Inducement Award Plan.
−Removed: The only persons eligible to receive grants of awards under the either the 2017 Inducement Plan or the 2019 Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1-that is, generally, a person not previously an employee or director of ours, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with us.
+Added: Our outstanding equity compensation arrangements that have not been approved by our stockholders consist of the 2017 Inducement Plan, the 2019 Inducement Plan and the 2020 Inducement Plan.
+Added: In April 2017, our board of directors adopted the 2017 Inducement Plan and reserved 800,000 shares of our common stock for issuance under 2017 the Inducement Plan.
+Added: In August 2019, our board of directors adopted the 2019 Inducement Plan and reserved 500,000 shares of our common stock for issuance under the 2019 Inducement Plan.
+Added: In March 2020, our board of directors adopted the 2020 Inducement Plan and reserved 800,000 shares of our common stock for issuance under the 2020 Inducement Plan.
+Added: The only persons eligible to receive grants of awards under the either the 2017 Inducement Plan, the 2019 Inducement Plan or the 2020 Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1-that is, generally, a person not previously an employee or director of ours, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with us.
An “Award” is any right to receive our common stock pursuant to the Inducement Plan, consisting of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs, or any other stock award.
3 unchanged sentences
We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K.
−Removed: Selected Financial Data
−Removed: The following selected balance sheet data for the years ended December 31, 2020 and 2019 and the statement of operations data for the years ended December 31, 2020, 2019 and 2018 should be read in conjunction with Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in conjunction with the consolidated financial statements, related notes and other financial information included elsewhere in this Annual Report.
−Removed: The selected consolidated results of operation data for the years ended December 31, 2017 and 2016 and the balance sheet data for the years ended December 31, 2018, 2017 and 2016 have been derived from audited consolidated financial statements not included herein.
−Removed: Our historical results are not necessarily indicative of the results to be expected in the future.
−Removed: ($ in thousands except for per share amounts)
−Removed: Balance Sheet Data:
−Removed: Total stockholders’ equity
−Removed: Statement of Operations Data:
−Removed: Collaboration revenue
−Removed: Operating expenses
−Removed: Loss from operations
−Removed: Interest and other income, net
−Removed: Loss before income taxes
−Removed: Income tax (expenses) benefit
−Removed: Unrealized gain/loss on marketable securities, net of tax
−Removed: Basic and dilutive loss per share
−Removed: The increase in total assets from $98.1 million as of December 31, 2016 to $169.3 million as of December 31, 2017 was primarily due to a capital raise of $64.8 million in net proceeds in November 2017 and receipt from Allergan of an upfront payment of $50.0 million in February 2017.
−Removed: The increase in total assets from $169.3 million as of December 31, 2017 to $268.0 million as of December 31, 2018 was primarily due to a capital raise of $155.4 million in net proceeds to us in July 2018.
−Removed: The increase in total assets from $268.0 million as of December 31, 2018 to $339.9 million as of December 31, 2019 is primarily due to a capital raise of $134.7 million in net proceeds in December 2019.
−Removed: The decrease in total assets from $339.9 million as of December 31, 2019 to $283.3 million as of December 31, 2020 is primarily due to cash used in operations.
−Removed: Our operating expenses have increased year over year primarily due to increases in research and development activities and an increase in our total headcount.
−Removed: See Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for a discussion on results of operations and financing activities since 2018.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.